These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 25111859)
21. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129 [TBL] [Abstract][Full Text] [Related]
22. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685 [TBL] [Abstract][Full Text] [Related]
23. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. Edeline J; Benabdelghani M; Bertaut A; Watelet J; Hammel P; Joly JP; Boudjema K; Fartoux L; Bouhier-Leporrier K; Jouve JL; Faroux R; Guerin-Meyer V; Kurtz JE; Assénat E; Seitz JF; Baumgaertner I; Tougeron D; de la Fouchardière C; Lombard-Bohas C; Boucher E; Stanbury T; Louvet C; Malka D; Phelip JM J Clin Oncol; 2019 Mar; 37(8):658-667. PubMed ID: 30707660 [TBL] [Abstract][Full Text] [Related]
24. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. Kim ST; Jang KT; Lee SJ; Jang HL; Lee J; Park SH; Park YS; Lim HY; Kang WK; Park JO BMC Cancer; 2015 Jul; 15():530. PubMed ID: 26189560 [TBL] [Abstract][Full Text] [Related]
25. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446 [TBL] [Abstract][Full Text] [Related]
26. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C; Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238 [TBL] [Abstract][Full Text] [Related]
27. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Choi IS; Kim KH; Lee JH; Suh KJ; Kim JW; Park JH; Kim YJ; Kim JS; Kim JH; Kim JW Eur J Cancer; 2021 Sep; 154():288-295. PubMed ID: 34303267 [TBL] [Abstract][Full Text] [Related]
28. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213 [TBL] [Abstract][Full Text] [Related]
29. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. Phelip JM; Vendrely V; Rostain F; Subtil F; Jouve JL; Gasmi M; Michel P; Le Malicot K; Smith D; Seitz JF; Fauchart JP; Martin P; Bennouna J; Morin T; Bonnet I; Maingon P; Lepage C; Chauffert B Eur J Cancer; 2014 Nov; 50(17):2975-82. PubMed ID: 25241229 [TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Li J; Merl M; Lee MX; Kaley K; Saif MW Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915 [TBL] [Abstract][Full Text] [Related]
31. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. Ahn DH; Reardon J; Ahn CW; Bupathi M; Mikhail S; Wu CS; Bekaii-Saab T Int J Cancer; 2018 Apr; 142(8):1671-1675. PubMed ID: 29114851 [TBL] [Abstract][Full Text] [Related]
32. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer. Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988 [TBL] [Abstract][Full Text] [Related]
33. Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. Bréchon M; Dior M; Dréanic J; Brieau B; Guillaumot MA; Brezault C; Mir O; Goldwasser F; Coriat R Invest New Drugs; 2018 Feb; 36(1):156-162. PubMed ID: 28762171 [TBL] [Abstract][Full Text] [Related]
34. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981 [TBL] [Abstract][Full Text] [Related]
35. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ; J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661 [TBL] [Abstract][Full Text] [Related]
36. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839 [TBL] [Abstract][Full Text] [Related]
37. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010 [TBL] [Abstract][Full Text] [Related]
38. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study. Larsen FO; Markussen A; Diness LV; Nielsen D Oncology; 2018; 94(1):19-24. PubMed ID: 28930749 [TBL] [Abstract][Full Text] [Related]
40. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. Lamarca A; Benafif S; Ross P; Bridgewater J; Valle JW Eur J Cancer; 2015 Sep; 51(13):1694-703. PubMed ID: 26066735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]